Active Biotech Names Shareholder-Backed Nomination Committee Ahead of 2026 AGM

The latest update is out from Active Biotech AB ( (SE:ACTI) ).

Active Biotech AB has appointed its Nomination Committee in line with the mandate from the 2025 Annual General Meeting, based on the company’s three largest shareholders by votes as of 30 September 2025 together with the Chairman of the Board. The committee, chaired by Michael Shalmi and including representatives from MGA Holding, Sjuenda Holding and T-bolaget, will prepare proposals ahead of the 2026 AGM on board composition, chairman selection, director and committee remuneration, auditor appointments and the future Nomination Committee, underscoring ongoing shareholder influence over the company’s governance and strategic oversight as it advances its clinical-stage oncology and immunology pipeline.

The most recent analyst rating on (SE:ACTI) stock is a Sell with a SEK0.04 price target. To see the full list of analyst forecasts on Active Biotech AB stock, see the SE:ACTI Stock Forecast page.

More about Active Biotech AB

Active Biotech AB is a Swedish biotechnology company listed on Nasdaq Stockholm that develops first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical need and significant commercial potential. Its pipeline includes the wholly owned small-molecule immunomodulators tasquinimod, in clinical development for hematological malignancies such as myelofibrosis and multiple myeloma, and laquinimod, in development for inflammatory eye disorders including non-infectious uveitis, as well as naptumomab, a targeted anticancer immunotherapy partnered with NeoTX Therapeutics for advanced solid tumors.

YTD Price Performance: -8.70%

Average Trading Volume: 9,280,329

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK112.3M

See more insights into ACTI stock on TipRanks’ Stock Analysis page.